Skip to main content
Keyword
Specialties
Allergy & Immunology
Autoimmune
CardioVascular
Clinical Pathways
Dentistry
Dermatology
Emergency & Mobile Medicine
Endocrinology & Diabetes
Gastroenterology
Infectious Diseases
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Pediatrics
Podiatry
Population Health
Psychiatry & Behavioral Health
Pulmonology
Rheumatology & Arthritis
Surgery
Urology
Wound Care
Events
Education
About
Sign In
Search
Keyword
Specialties
Allergy & Immunology
Autoimmune
CardioVascular
Clinical Pathways
Dentistry
Dermatology
Emergency & Mobile Medicine
Endocrinology & Diabetes
Gastroenterology
Infectious Diseases
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Pediatrics
Podiatry
Population Health
Psychiatry & Behavioral Health
Pulmonology
Rheumatology & Arthritis
Surgery
Urology
Wound Care
Events
Education
About
Sign In
Search
Simone Oldani
Predictive impact of RNF43 mutation (mut) in pMMR/MSS BRAFV600E-mutated metastatic colorectal cancer (mCRC) patients (pts) treated with target therapy (TT) or chemotherapy (CT)
Encorafenib plus cetuximab is a standard option in the treatment of BRAFV600E mut mCRC pts pre-treated with at least one systemic therapy. RNF43 is a negative regulator of WNT pathway. A ...
Guglielmo Vetere ;
G. Fontanini ;
Rodrigo De Almeida Toledo ;
F. Bergamo ;
Giovanni Randon , MD;
Simone Oldani ;
Walter Ferrari Bravo ;
Gianmarco Ricagno ;
Paola Vignali ;
Sara Lonardi ;
E. Elez ;
R. Moretto ;
M. Germani ;
M. Giordano ;
Rossana Intini ;
C. Cremolini ;
Filippo Ghelardi ;
C. Ugolini ;
06/25/2023
Featured Webinar
Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications
Upcoming Events
February 2 – February 5
February 27 – March 1
March 17 – March 19
March 27 – March 30
March 31 – April 2
April 21 – April 24
April 30 – May 4
April 30 – May 5
May 1 – May 3
May 19 – May 21
See Full Calendar